Advertisement

Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function

Published:December 17, 2016DOI:https://doi.org/10.1016/j.amjcard.2016.11.043
      Implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT) reduce mortality in many patients with heart failure (HF), but the current use and effectiveness of ICD/CRT in patients with chronic kidney disease (CKD) are uncertain. We examined associations between kidney function and guideline-recommended prescription of ICD/CRT in the Get With The Guidelines–Heart Failure registry, a performance improvement program for hospitalized patients with HF. We compared differences in ICD and CRT prescription between the following categories of estimated glomerular filtration rate (eGFR; mL/min/1.73 m2): ≥60, 59 to 30, <30, and dialysis dependent. From 2008 through 2014, 26,286 patients were eligible for ICD or CRT, and 16,123(61%) had an eGFR <60. De novo ICD and CRT prescription in this group was low at 45% and 30.5%, respectively. Compared to patients with eGFR ≥60, patients with eGFR 30 to 59 were more likely to receive an ICD (adjusted odds ratio [aOR] 1.08, 95% confidence intervals [CI] 1.01 to 1.14), whereas dialysis patients were less likely (aOR 0.61, 95% CI 0.5 to 0.76). Worse kidney function was associated with a decreased likelihood of CRT prescription (aOR 0.97 per 10 ml/min eGFR decrease, p = 0.03). During the study period, the likelihood of both ICD and CRT prescription increased over time among patients with CKD (ICD aOR 1.12, 95% CI 1.07 to 1.18; CRT aOR 1.14, 95% CI 1.06 to 1.23, per year). Prescription of an ICT/CRT was associated with greater 1-year survival in all eGFR groups. In conclusion, there are significant CKD-based differences in prescription of ICD and CRT in HF. However, given the current state of evidence, it is unclear whether improved prescription of ICD and CRT in the CKD population will result in improvement in outcomes.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cannizzaro L.A.
        • Piccini J.P.
        • Patel U.D.
        • Hernandez A.F.
        Device therapy in heart failure patients with chronic kidney disease.
        J Am Coll Cardiol. 2011; 58: 889-896
        • Patel U.D.
        • Hernandez A.F.
        • Liang L.
        • Peterson E.D.
        • LaBresh K.A.
        • Yancy C.W.
        • Albert N.M.
        • Ellrodt G.
        • Fonarow G.C.
        Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines—Heart Failure Program study.
        Am Heart J. 2008; 156: 674-681
        • Fonarow G.C.
        • Yancy C.W.
        • Albert N.M.
        • Curtis A.B.
        • Stough W.G.
        • Gheorghiade M.
        • Heywood J.T.
        • McBride M.L.
        • Mehra M.R.
        • O'Connor C.M.
        • Reynolds D.
        • Walsh M.N.
        Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF.
        Circ Heart Fail. 2008; 1: 98-106
        • Heywood J.T.
        • Fonarow G.C.
        • Yancy C.W.
        • Albert N.M.
        • Curtis A.B.
        • Stough W.G.
        • Gheorghiade M.
        • McBride M.L.
        • Mehra M.R.
        • O'Connor C.M.
        • Reynolds D.
        • Walsh M.N.
        Influence of renal function on the use of guideline-recommended therapies for patients with heart failure.
        Am J Cardiol. 2010; 105: 1140-1146
        • Russo A.M.
        • Stainback R.F.
        • Bailey S.R.
        • Epstein A.E.
        • Heidenreich P.A.
        • Jessup M.
        • Kapa S.
        • Kremers M.S.
        • Lindsay B.D.
        • Stevenson L.W.
        ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance.
        J Heart Rhythm Soc. 2013; 10: e11-e58
        • Pun P.H.
        The interplay between CKD, sudden cardiac death, and ventricular arrhythmias.
        Adv Chronic Kidney Dis. 2014; 21: 480-488
        • Hess P.L.
        • Hellkamp A.S.
        • Peterson E.D.
        • Sanders G.D.
        • Al-Khalidi H.R.
        • Curtis L.H.
        • Hammill B.G.
        • Pun P.H.
        • Curtis J.P.
        • Anstrom K.J.
        • Hammill S.C.
        • Al-Khatib S.M.
        Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease.
        Circ Arrhythm Electrophysiol. 2014; 7: 793-799
        • Pun P.H.
        • Hellkamp A.S.
        • Sanders G.D.
        • Middleton J.P.
        • Hammill S.C.
        • Al-Khalidi H.R.
        • Curtis L.H.
        • Fonarow G.C.
        • Al-Khatib S.M.
        Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.
        Nephrol Dial Transpl. 2015; 30: 829-835
        • Pun P.H.
        • Al-Khatib S.M.
        • Han J.Y.
        • Edwards R.
        • Bardy G.H.
        • Bigger J.T.
        • Buxton A.E.
        • Moss A.J.
        • Lee K.L.
        • Steinman R.
        • Dorian P.
        • Hallstrom A.
        • Cappato R.
        • Kadish A.H.
        • Kudenchuk P.J.
        • Mark D.B.
        • Hess P.L.
        • Inoue L.Y.
        • Sanders G.D.
        Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.
        Am J Kidney Dis. 2014; 64: 32-39
        • Smaha L.A.
        • American Heart A.
        The American Heart Association Get With The Guidelines program.
        Am Heart J. 2004; 148: S46-48
        • Epstein A.E.
        • DiMarco J.P.
        • Ellenbogen K.A.
        • Estes 3rd, N.A.
        • Freedman R.A.
        • Gettes L.S.
        • Gillinov A.M.
        • Gregoratos G.
        • Hammill S.C.
        • Hayes D.L.
        • Hlatky M.A.
        • Newby L.K.
        • Page R.L.
        • Schoenfeld M.H.
        • Silka M.J.
        • Stevenson L.W.
        • Sweeney M.O.
        • American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, Heart Rhythm Society
        2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
        Circulation. 2013; 127: e283-e352
        • Hammill B.G.
        • Hernandez A.F.
        • Peterson E.D.
        • Fonarow G.C.
        • Schulman K.A.
        • Curtis L.H.
        Linking inpatient clinical registry data to Medicare claims data using indirect identifiers.
        Am Heart J. 2009; 157: 995-1000
        • Levey A.S.
        • Stevens L.A.
        Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions.
        Am J Kidney Dis. 2010; 55: 622-627
        • Pun P.H.
        • Schumm D.
        • Sanders G.D.
        • Hickey D.
        • Middleton J.P.
        • Clapp-Channing N.
        • Al-Khatib S.M.
        A pilot study using an implantable device to characterize cardiac arrhythmias in hemodialysis patients: implications for future research.
        Ann Noninvasive Electrocardiol. 2012; 17: 159
        • Pun P.H.
        • Smarz T.R.
        • Honeycutt E.F.
        • Shaw L.K.
        • Al-Khatib S.M.
        • Middleton J.P.
        Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease.
        Kidney Int. 2009; 76: 652-658
        • USRDS Annual Data Report
        Atlas of End-stage Renal Disease in the United States.
        2015
        • Passman R.
        • Herzog C.A.
        End-stage renal disease: sudden cardiac death: stratifying risk in dialysis patients.
        Nat Rev Nephrol. 2011; 7: 133-135
        • Dasgupta A.
        • Montalvo J.
        • Medendorp S.
        • Lloyd-Jones D.M.
        • Ghossein C.
        • Goldberger J.
        • Passman R.
        Increased complication rates of cardiac rhythm management devices in ESRD patients.
        Am J Kidney Dis. 2007; 49: 656-663
        • Buiten M.S.
        • De Bie M.K.
        • Van Der Heijden A.C.
        • Rotmans J.I.
        • Bootsma M.
        • Marc Groeneveld J.H.
        • Wolterbeek R.
        • Rabelink T.J.
        • Jukema J.W.
        • Schalij M.J.
        • Van Erven L.
        Chronic kidney disease and implantable cardioverter defibrillator related complications: 16 years of experience.
        J Cardiovasc Electrophysiol. 2014; 25: 998-1004
        • Boriani G.
        • Savelieva I.
        • Dan G.A.
        • Deharo J.C.
        • Ferro C.
        • Israel C.W.
        • Lane D.A.
        • La Manna G.
        • Morton J.
        • Mitjans A.M.
        • Vos M.A.
        • Turakhia M.P.
        • Lip G.Y.
        • Document reviewers
        Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.
        Europace. 2015; 17: 1169-1196
        • Cleland J.G.
        • Daubert J.C.
        • Erdmann E.
        • Freemantle N.
        • Gras D.
        • Kappenberger L.
        • Tavazzi L.
        • Cardiac Resynchronization-Heart Failure Study Investigators
        The effect of cardiac resynchronization on morbidity and mortality in heart failure.
        N Engl J Med. 2005; 352: 1539-1549
        • Garg N.
        • Thomas G.
        • Jackson G.
        • Rickard J.
        • Nally Jr., J.V.
        • Tang W.H.
        • Navaneethan S.D.
        Cardiac resynchronization therapy in CKD: a systematic review.
        Clin J Am Soc Nephrol. 2013; 8: 1293-1303
        • Friedman D.J.
        • Singh J.P.
        • Curtis J.P.
        • Tang W.H.
        • Bao H.
        • Spatz E.S.
        • Hernandez A.F.
        • Patel U.D.
        • Al-Khatib S.M.
        Comparative effectiveness of CRT-D versus defibrillator alone in HF patients with moderate-to-severe chronic kidney disease.
        J Am Coll Cardiol. 2015; 66: 2618-2629
        • Hoke U.
        • Khidir M.J.
        • van der Velde E.T.
        • Schalij M.J.
        • Bax J.J.
        • Delgado V.
        • Marsan N.A.
        Cardiac resynchronization therapy in CKD stage 4 patients.
        Clin J Am Soc Nephrol. 2015; 10: 1740-1748
        • Singal G.
        • Upadhyay G.A.
        • Borgquist R.
        • Friedman D.J.
        • Chatterjee N.A.
        • Kandala J.
        • Park M.Y.
        • Orencole M.
        • Dec G.W.
        • Picard M.H.
        • Singh J.P.
        • Mela T.
        Renal response in patients with chronic kidney disease predicts outcome following cardiac resynchronization therapy.
        Pacing Clin Electrophysiol. 2015; 38: 1192-1200